Bachem Holding AG stock (CH0012530207): Target price raised on peptide strength

Bachem Holding AG, a Swiss leader in peptide manufacturing, saw its target price raised to CHF 77.9 from CHF 73.8, reflecting strong momentum in its peptide business, Marketscreener as of recent update. The adjustment signals confidence in the growth story despite shares trading near CHF 82, viewed as fairly priced short-term. This comes amid positive sector tailwinds for biotech APIs.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

Bachem Holding AG: core business model

Bachem Holding AG specializes in process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech sectors. The company also develops biochemical products for research, including fluorescent dyes for FRET analysis and glycosylated peptides, Marketscreener company profile. With production sites in Switzerland and the US, Bachem serves global clients under Bachem and Clinalfa brands.

Employing around 2,363 people, Bachem focuses on innovation-driven peptide and oligonucleotide production, positioning it as a key supplier in drug development pipelines.

Main revenue and product drivers for Bachem Holding AG

Peptides form the core revenue driver, fueled by demand for custom APIs in therapeutics. The recent target price hike underscores this momentum, with analysts noting intact growth potential amid expanding biotech needs, per recent coverage.

US operations enhance Bachem's appeal to American pharma firms, contributing to diversified revenue. Shares recently traded at CHF 79.25, down 1.37% intraday but up 7.17% short-term and 32.30% longer-term, Marketscreener as of recent data.

Industry trends and competitive position

The peptide synthesis market benefits from rising biologics and personalized medicine demand. Bachem's dual-site manufacturing bolsters supply chain resilience, a plus for US investors tracking biotech enablers amid regulatory scrutiny on outsourcing.

Why Bachem Holding AG matters for US investors

Listed on SIX Swiss Exchange, Bachem's US facility supports American biotech giants, offering indirect exposure to US drug innovation without pure-play volatility. Its API role in clinical pipelines ties performance to FDA approvals and sector funding cycles relevant to US portfolios.

Conclusion

The target price increase to CHF 77.9 highlights Bachem Holding AG's peptide strength, with shares holding steady near CHF 82 on SIX Swiss Exchange. US production and biotech ties provide cross-Atlantic relevance, though valuation now reflects near-term stability. Investors monitor API demand and sector trends for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.